Program
vunakizumab
Also written as “SHR-1314”, “SHR-1314 injection” and “SHR-1314 Injection”.
Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Non-Radiographic Axial Spondyloarthritis · Graves Ophthalmopathy · Spondylitis, Ankylosing, led by Jiangsu HengRui Medicine.
Drug pageVunakizumab: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 174 open or running | phase 4since Jan 7, 2025 | Sep 20, 2016 | Mar 2027phase 4 · NCT06779097 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 1 earlier study, Sep 20, 2016 to Sep 20, 2016.
- Jun 9, 2016Named vunakizumabINNProposed as its International Nonproprietary Name in WHO's List 115 · before, SHR-1314
- Jan 22, 2018Phase 2 study in Moderate-to-severe Chronic Plaque PsoriasisNCT03463187 · 211 enrolled · United States, Australia, China
- Sep 6, 20182 phase 1 studiesNCT03710681, NCT03704428
- Sep 27, 2019Phase 2 study in Plaque PsoriasisNCT04121143 · 120 enrolled · China
- Mar 24, 2020Phase 1 study in PharmacokineticNCT04326881 · 30 enrolled
- Aug 23, 2020Phase 1 study in BioequivalenceNCT04527484 · 130 enrolled
- Apr 7, 20212 phase 3 studiesNCT04840485, NCT04839016
- Jun 7, 2021Phase 2 study in Lupus NephritisNCT04924296 · 60 enrolled
- Sep 15, 2021Phase 2 study in Arthritis, PsoriaticNCT05055934 · 112 enrolled · China
- May 23, 2022Phase 2 study in Active Moderate to Severe Graves' OrbitopathyNCT05394857 · 7 enrolled · China
- Dec 4, 2023Phase 1 study in Moderate-to-Severe Plaque PsoriasisNCT06182384 · 46 enrolled · China
- Oct 10, 2024Phase 3 study in Arthritis, PsoriaticNCT06640257 · 208 enrolled · China
- Jan 7, 2025Phase 4 study in Moderate to Severe Plaque PsoriasisNCT06779097 · 1,564 planned · China
- Feb 11, 2025Phase 3 study in Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque PsoriasisNCT06833307 · 90 planned · China
- Mar 2, 2025Phase 3 study in Active Non-radiographic Axial SpondyloarthritisNCT06860750 · 380 planned · China
Ahead
- Mar 2027Primary completion: phase 4 study in Moderate to Severe Plaque PsoriasisNCT06779097
- Feb 2028Primary completion: phase 3 study in Active Non-radiographic Axial SpondyloarthritisNCT06860750
TargetBeta
“Interleukin 17A inhibitor”ChEMBL 37, by rule
Other programs on IL17A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| secukinumabrule | Novartis | phase 4 | 128 |
| ixekizumabrule | Eli Lilly | phase 4 | 38 |
| bimekizumabrule | UCB | phase 3 | 43 |
| sonelokimabrule | moonlake-immunotherapeutics-ag | phase 3 | 12 |
| simepdekinra | Eli Lilly | phase 2 | 7 |
| tibulizumabrule | Eli Lilly | phase 2 | 5 |
| SCT650Crule | Sinocelltech Group | phase 2 | 3 |
| UA026rule | usynova-pharmaceuticals-ltd | phase 1 | 1 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06860750Active Non-radiographic Axial Spondyloarthritis · China | 3 | Recruiting | Feb 2028 | 380 |
| NCT06833307Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis · China | 3 | Not yet recruiting | Jul 2026 | 90 |
| NCT06779097Moderate to Severe Plaque Psoriasis · China | 4 | Not yet recruiting | Mar 2027 | 1,564 |
| NCT06640257Arthritis, Psoriatic · China | 3 | Active, not recruiting | Jun 5, 2026 | 208 |
| NCT06182384Moderate-to-Severe Plaque Psoriasis · China | 1 | Completed | May 13, 2024 | 46 |
| NCT05394857Active Moderate to Severe Graves' Orbitopathy · China | 2 | Terminated | Aug 22, 2023 | 7 |
| NCT05055934Arthritis, Psoriatic · China | 2 | Completed | Jun 5, 2024 | 112 |
| NCT04924296Lupus Nephritis | 2 | UNKNOWN | Dec 25, 2021 | 60 |
| NCT04839016Moderate-to-Severe Plaque Psoriasis | 3 | UNKNOWN | Aug 30, 2023 | 660 |
| NCT04840485Spondylitis, Ankylosing · China | 3 | Completed | Nov 3, 2023 | 548 |
| NCT04527484Bioequivalence | 1 | UNKNOWN | Jan 10, 2021 | 130 |
| NCT04326881Pharmacokinetic | 1 | UNKNOWN | Jul 7, 2020 | 30 |
| NCT04121143Plaque Psoriasis · China | 2 | Suspended | Jun 30, 2020 | 120 |
| NCT03704428Axial Spondyloarthritis · China | 1 | Completed | Jan 14, 2020 | 45 |
| NCT03710681Moderate-to-severe Plaque Psoriasis · China | 1 | UNKNOWN | Apr 21, 2019 | 16 |
| NCT03463187Moderate-to-severe Chronic Plaque Psoriasis · United States, Australia, China | 2 | Completed | Aug 31, 2020 | 211 |
| NCT02934412Psoriasis · Australia | 1 | Completed | Jun 30, 2017 | 40 |
How it is read
Names in the registry
- “SHR-1314”, 14 entries
- “SHR-1314 injection”, 2 entries
- “SHR-1314 Injection”, 1 entry
- “Vunakizumab (IL-17A inhibitor)”, 1 entry
- “IL-17A Antagonist”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 8 studies
- Arthritis, Psoriatic, 2 studies
- Non-Radiographic Axial Spondyloarthritis, 1 study
- Graves Ophthalmopathy, 1 study
- Spondylitis, Ankylosing, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.